Fri Sep 20 12:43:00 UTC 2024: ## Novo Nordisk’s New Obesity Drug Shows Promise in Phase 2a Trial
**Bagsværd, Denmark, September 20, 2024** – Novo Nordisk today announced promising results from a phase 2a clinical trial of monlunabant, a novel oral medication for obesity. The drug, acquired from Inversago Pharmaceuticals in August 2023, targets the cannabinoid receptor 1 (CB1), a key player in regulating appetite and metabolism.
The trial involved 243 participants with obesity and metabolic syndrome. They were randomly assigned to receive one of four treatments: placebo, or monlunabant at 10 mg, 20 mg, or 50 mg daily for 16 weeks.
All doses of monlunabant resulted in statistically significant weight loss compared to placebo. Participants on the 10 mg dose achieved an average weight loss of 7.1 kg, compared to just 0.7 kg for the placebo group. While higher doses showed limited additional weight loss, the trial indicated that monlunabant has potential as an effective treatment for obesity.
The most common side effects were gastrointestinal issues, primarily mild to moderate and dose-dependent. Increased rates of mild to moderate neuropsychiatric side effects, such as anxiety, irritability, and sleep disturbances, were also reported with monlunabant, though no serious adverse events were linked to these side effects.
“The phase 2a results highlight the weight-lowering potential of monlunabant,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “Obesity is a complex disease with a significant unmet need, and monlunabant, with its unique mechanism of action, holds promise for treating this condition.”
Based on these positive results, Novo Nordisk plans to launch a larger phase 2b trial in 2025. This trial will further investigate the optimal dosing and safety profile of monlunabant over a longer duration in a global population.
Monlunabant is an inverse agonist of the CB1 receptor, which plays a crucial role in metabolic and appetite regulation in both the central nervous system and peripheral tissues. This unique mechanism of action makes monlunabant a promising new addition to the treatment landscape for obesity.
First Piper 